

## Tradjenta (Type 2 Diabetes) - Analysis and Forecasts to 2020

Description: Tradjenta (Type 2 Diabetes) – Analysis and Forecasts to 2020

### Summary

GlobalData's pharmaceuticals report, "Tradjenta (Type 2 Diabetes) – Analysis and Forecasts to 2020" provides Tradjenta sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2011-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

### Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Tradjenta
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Tradjenta including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2011-2020 for Tradjenta in the seven major markets

### Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

### Keywords

Tradjenta, Type 2 Diabetes, Diabetes, linagliptin, Sales forecast, DPP-IV inhibitor, Phase III, Phase 3, Pipeline, Victoza, Onglyza, Januvia, Janumet, Lantus, Boehringer Ingelheim

Contents:	1
	1
	1.1 List of Tables
	1.2 List of Figures
	2 Introduction
	2.1 Diabetes
	2.2 Epidemiology
	2.2.1 Prevalence
	2.2.2 Mortality
	2.3 Etiology and Risk Factors
	2.3.1 Obesity
	2.3.2 Sedentary Lifestyle
	2.3.3 Family History and Genetics
	2.3.4 Ethnicity
	2.3.5 Old Age
	2.4 Economic Impact of Diabetes

- 2.5 GlobalData Report Guidance
- 3 Type 2 Diabetes: Market Characterization
  - 3.1 Type 2 Diabetes Market
  - 3.2 Type 2 Diabetes Market Forecasts
  - 3.3 Type 2 Diabetes Market: Drivers and Restraints
    - 3.3.1 Drivers
    - 3.3.2 Restraints
- 4 Classification of Diabetes
  - 4.1 Types of Diabetes
    - 4.1.1 Type 1 Diabetes
    - 4.1.2 Type 2 Diabetes
    - 4.1.3 Gestational Diabetes
  - 4.2 Diabetes Complications
    - 4.2.1 Cardiovascular Disease
    - 4.2.2 Nephropathy
    - 4.2.3 Neuropathy
    - 4.2.4 Amputation
    - 4.2.5 Retinopathy
- 5 Evolution of Anti-Diabetic Treatments
- 6 Medications
  - 6.1 Insulin
  - 6.2 Oral Medications
    - 6.2.1 Sulfonylureas (SUR)
    - 6.2.2 Biguanides (BGDs)
    - 6.2.3 Alpha-Glucosidase Inhibitors (AGI)
    - 6.2.4 Meglitinides
    - 6.2.5 Thiazolidinediones (TZDs)
    - 6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors
    - 6.2.7 Oral Combination Therapy
  - 6.3 Other Injectionable Medications
    - 6.3.1 Pramlintide
    - 6.3.2 Exenatide
  - 6.4 Market Share as per Classes in Type 2 Diabetes
- 7 Tradjenta (linagliptin)
  - 7.1 Introduction
  - 7.2 Mechanism of Action
  - 7.3 Clinical Studies
  - 7.4 Approval Of Tradjenta
  - 7.5 Factors Affecting Sales of Tradjenta
    - 7.5.1 Me Too Drug
    - 7.5.2 Advantage of DPP IV Inhibitors
    - 7.5.3 Black box Warnings
    - 7.5.4 Potential Benefits of Tradjenta over Januvia and Onglyza
  - 7.6 Drug Evaluation
    - 7.6.1 Drug Risk Benefit Score
    - 7.6.2 Intensity of Competition
  - 7.7 Sales Forecasts
    - 7.7.1 Target Patient Pool for Tradjenta
    - 7.7.2 Dosing
    - 7.7.3 Annual Cost of Therapy
    - 7.7.4 Market Penetration
    - 7.7.5 Sales Projection of Tradjenta
- 8 Diabetes Market: Appendix
  - 8.1 Market Definitions
  - 8.2 List of Abberiviations
  - 8.3 Research Methodology
    - 8.3.1 Coverage
    - 8.3.2 Secondary Research
    - 8.3.3 Forecasting
    - 8.3.4 Number of patients approved to take the drug
    - 8.3.5 Net Penetration of Drug
    - 8.3.6 Net Annual Dosing
    - 8.3.7 Annual Cost of Therapy

- 8.4 Drug Sales Estimates Model
- 8.5 Contact Us
- 8.6 Disclaimer
- 8.7 Sources

## 1.1 List of Tables

- Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030
- Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030
- Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures (\$bn), 2010
- Table 4: Type 2 Diabetes, World, Major Marketed Drugs by Sales (\$m), 2010
- Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III Clinical Trials
- Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030
- Table 7: Overweight-, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005
- Table 8: Diabetes Drugs Evolution
- Table 9: Study Details
- Table 10: Drug Risk Benefit Score of Tradjenta
- Table 11: Tradjenta, Type 2 Diabetes, Global, Sales Forecasts (\$m), 2011–2020
- Table 12: Tradjenta, Type 2 Diabetes, The US, Sales Forecasts (\$m), 2011–2020
- Table 13: Tradjenta, Type 2 Diabetes, The UK, Sales Forecasts (\$m), 2011–2020
- Table 14: Tradjenta, Type 2 Diabetes, France, Sales Forecasts (\$m), 2011–2020
- Table 15: Tradjenta, Type 2 Diabetes, Germany, Sales Forecasts (\$m), 2011–2020
- Table 16: Tradjenta, Type 2 Diabetes, Italy, Sales Forecasts (\$m), 2011–2020
- Table 17: Tradjenta, Type 2 Diabetes, Spain, Sales Forecasts (\$m), 2011–2020
- Table 18: Tradjenta, Type 2 Diabetes, Japan, Sales Forecasts (\$m), 2011–2020

## 1.2 List of Figures

- Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010
- Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030
- Figure 3: Diabetes, World, Mortality, 2010
- Figure 4: Top 10 Causes of Mortality, Worldwide, 2008
- Figure 5: Type 2 Diabetes, Global, Market Size Forecasts (\$bn), 2010–2020
- Figure 6: Mechanism of Action of Sulfonylureas
- Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors
- Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors
- Figure 9: Mechanism of Action of Thiazolidinediones
- Figure 10: Mechanism of Action of DPP IV Inhibitors
- Figure 11: Type 2 Diabetes, Global, Branded Market Share by Value, By Class (%), 2010
- Figure 12: Tradjenta, Type 2 Diabetes, Global, Sales Forecasts (\$m), 2011–2020
- Figure 13: Tradjenta, Type 2 Diabetes, The US, Sales Forecasts (\$m), 2011–2020
- Figure 14: Tradjenta, Type 2 Diabetes, The UK, Sales Forecasts (\$m), 2011–2020
- Figure 15: Tradjenta, Type 2 Diabetes, France, Sales Forecasts (\$m), 2011–2020
- Figure 16: Tradjenta, Type 2 Diabetes, Germany, Sales Forecasts (\$m), 2011–2020
- Figure 17: Tradjenta, Type 2 Diabetes, Italy, Sales Forecasts (\$m), 2011–2020
- Figure 18: Tradjenta, Type 2 Diabetes, Spain, Sales Forecasts (\$m), 2011–2020
- Figure 19: Tradjenta, Type 2 Diabetes, Japan, Sales Forecasts (\$m), 2011–2020
- Figure 20: Tradjenta, Type 2 Diabetes, Global, Sales Distribution (%), 2020
- Figure 21: Patients Approved for the Drug

Ordering: Order Online - <http://www.researchandmarkets.com/reports/2075323/>

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,  
Guinness Centre,  
Taylors Lane,  
Dublin 8,  
Ireland.



## Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

<http://www.researchandmarkets.com/contact/>

## Order Information

Please verify that the product information is correct and select the format(s) you require.

Product Name: Tradjenta (Type 2 Diabetes) - Analysis and Forecasts to 2020  
Web Address: <http://www.researchandmarkets.com/reports/2075323/>  
Office Code: SCBT4500

## Product Formats

Please select the product formats and quantity you require:

	Quantity	
Electronic (PDF) - Site License:	<input type="checkbox"/>	EUR 3279
Electronic (PDF) - Single User:	<input type="checkbox"/>	EUR 1640
Electronic (PDF) - Enterprisewide:	<input type="checkbox"/>	EUR 4919

## Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: Mr  Mrs  Dr  Miss  Ms  Prof

First Name: \_\_\_\_\_ Last Name: \_\_\_\_\_

Email Address: \* \_\_\_\_\_

Job Title: \_\_\_\_\_

Organisation: \_\_\_\_\_

Address: \_\_\_\_\_

City: \_\_\_\_\_

Postal / Zip Code: \_\_\_\_\_

Country: \_\_\_\_\_

Phone Number: \_\_\_\_\_

Fax Number: \_\_\_\_\_

\* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)

**Payment Information**

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card:
  - American Express
  - Diners Club
  - Master Card
  - Visa

Cardholder's Name \_\_\_\_\_

Cardholder's Signature \_\_\_\_\_

Expiry Date \_\_\_\_\_ | \_\_\_\_\_

Card Number \_\_\_\_\_

CVV Number \_\_\_\_\_

Issue Date \_\_\_\_\_ | \_\_\_\_\_

(for Diners Club only)

- Pay by check:

Please post the check, accompanied by this form, to:

Research and Markets,  
Guinness Center,  
Taylors Lane,  
Dublin 8,  
Ireland.

- Pay by wire transfer:

Please transfer funds to:

Account number	833 130 83
Sort code	98-53-30
Swift code	ULSBIE2D
IBAN number	IE78ULSB98533083313083
Bank Address	Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: \_\_\_\_\_

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at <http://www.researchandmarkets.com/info/terms.asp>

**Please fax this form to:**  
**(646) 607-1907 or (646) 964-6609 - From USA**  
**+353-1-481-1716 or +353-1-653-1571 - From Rest of World**